Search Results

By Matthew Stenger  / Monday, June 15, 2015 10:38 AM

Denosumab Reduces Clinical Fracture Risk in Postmenopausal Women Receiving Aromatase Inhibitors

In a phase III trial (ABCSG-18) reported in The Lancet, Gnant et al found that adjuvant denosumab (Xgeva) reduced the risk of clinical fracture in women with breast cancer receiving aromatase inhibitor therapy. Study Details In the double-blind study, 3,420 women from Austria and Sweden with...